Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882382 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C9MCHR1SMN1; SMN2GRM5 | |
| SCHEMBL4889001 | 0.85 | CYP3A4 (0.72) | CYP3A4CYP2C9MCHR1LMNAPOLB | |
| SCHEMBL4885288 | 0.83 | CYP3A4 (0.73) | CYP3A4CYP2C9MCHR1CYP1A2CYP2D6 | |
| SCHEMBL2191140 | 0.78 | MEN1 (0.51) | CYP3A4CYP2C9LMNAPOLBMAPT | |
| SCHEMBL4878917 | 0.76 | CYP3A4 (0.77) | CYP3A4CYP2C9MCHR1MEN1KMT2A | |
| SCHEMBL4888752 | 0.75 | CYP3A4 (0.42) | CYP3A4CYP2C9MCHR1POLBMAPT | |
| SCHEMBL4886747 | 0.74 | CYP3A4 (0.71) | CYP3A4CYP2C9MCHR1GRM5CYP1A2 | |
| SCHEMBL14021269 | 0.73 | CYP3A4 (0.44) | CYP3A4CYP2C9MCHR1LMNACYP1A2 | |
| SCHEMBL14021374 | 0.73 | CYP3A4 (0.85) | CYP3A4CYP2C9MCHR1CYP1A2CYP2D6 | |
| SCHEMBL4884572 | 0.73 | CYP3A4 (0.58) | CYP3A4CYP2C9MCHR1GRM5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | claimed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | CYP3A4 215/4885CYP2C9 1357/4885MCHR1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.